Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

EGFR mutations as a predictive marker of cytotoxic chemotherapy.

Lung cancer (Amsterdam, Netherlands) - 1 Aug 2012

Park Jin Hyun, Lee Se-Hoon, Keam Bhumsuk, Kim Tae Min, Kim Dong-Wan, Yang Seok-Chul, Kim Young Whan, Heo Dae Seog

Abstract excerpt

BACKGROUND: Epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC) are important predictive markers for the response to EGFR-tyrosine kinase inhibitors (EGFR-TKIs). Whether EGFR mutations can also predict the clinical outcomes in NSCLC patients receiving chemotherapy has not yet been established. METHODS: We included 217 locally advanced/metastatic NSCLC cases in our study cohort....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Lung Neoplasms

Share to Prognosis

Share to Survival Analysis

Share to Treatment Outcome

Source

Identifiers

PMID: 22521649
DOI: 10.1016/j.lungcan.2012.03.020

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

EGFR mutations as a predictive marker of cytotoxic chemotherapy.PMID 22521649Read ↗

Predictive value of EGFR mutation in non-small-cell lung cancer patients treated with platinum doublet postoperative chemotherapy.Semantic proximity Read ↗

Response to first-line chemotherapy in patients with non-small-cell lung cancer according to epidermal growth factor receptor and K-RAS mutation status.Semantic proximity Read ↗

Advances in EGFR as a Predictive Marker in Lung Adenocarcinoma.Semantic proximity Read ↗

Correlation between EGFR mutation status and response to first-line platinum-based chemotherapy in patients with advanced non-small cell lung cancerSemantic proximity Read ↗

Comparison of the Efficacy between Pemetrexed plus Platinum and Non-Pemetrexed plus Platinum as First-Line Treatment in Patients with Wild-Type Epidermal Growth Factor Receptor Nonsquamous Non-Small Cell Lung Cancer: A Retrospective Analysis.Semantic proximity Read ↗

Cytotoxic chemotherapy may overcome the development of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) therapy.Semantic proximity Read ↗

Pemetrexed plus platinum versus pemetrexed alone in non-small cell lung cancer patients who have progressed after first-line EGFR TKIs.Semantic proximity Read ↗

Epidermal growth factor receptor mutations and response to chemotherapy in patients with non-small-cell lung cancer.Semantic proximity Read ↗

Biological prognostic and predictive factors in lung cancer.Semantic proximity Read ↗

[The importance of p53 and ras mutation as predictive markers for adjuvant chemotherapy in non-small-cell lung cancer].Semantic proximity Read ↗

[Outcomes of chemotherapy in patients with EGFR mutation-negative non-small cell lung cancer].Semantic proximity Read ↗

Prognostic and predictive value of epidermal growth factor receptor tyrosine kinase domain mutation status and gene copy number for adjuvant chemotherapy in non-small cell lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.